Atamyo Therapeutics
Clinical trials sponsored by Atamyo Therapeutics, explained in plain language.
-
Gene therapy trial offers hope for rare muscle disease
Disease control OngoingThis early-stage study is testing whether a new gene therapy called GNT0006 is safe for people with FKRP-related limb-girdle muscular dystrophy (LGMDR9). Six patients will receive the treatment, which delivers a working copy of the FKRP gene directly to muscle cells. Researchers …
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
First gene therapy tested in children with rare muscle disease
Disease control OngoingThis early-stage study is testing the safety of a single-dose gene therapy called ATA-200 in children with a rare genetic muscle disorder called limb girdle muscular dystrophy type 2C. The therapy aims to deliver a working copy of a faulty gene directly into the body via an intra…
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
Study withdrawn before launch: planned research to map rare muscle disease
Knowledge-focused TerminatedThis study aimed to track how a rare genetic muscle disease (LGMDR5) changes over two years in patients aged 6 to 35. It planned to measure walking, arm function, breathing, and muscle health to better understand the disease. The goal was to gather information to help design futu…
Sponsor: Atamyo Therapeutics • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC